Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1395 results about "Blood pump" patented technology

The blood pump was patented in 1855 by Porter and Bradley and was hand operated. A modification first named surgical pump, designed and manufactured by E. E. Allen in 1887, was intended for direct blood transfusion. Truax, who also distributed and promoted the Allen pump with one roller, developed the first double roller pump in 1899. In the following decades, several researchers, including Beck, Van Allen, Bayliss and Müller as well as Henry and Jouvelet, refined the apparatus and recommended the use of roller pumps for blood transfusion and other applications. After further modifications made by DeBakey in 1934, and application of this pump in one of the first heart-lung machines constructed by Gibbon, DeBakey's name became inseparably attached to this type of pump. For perfusion experiments, an electrically powered roller pump was first used by Fleisch in 1935. Today, the roller pump is the most frequently used blood pump for cardiopulmonary bypass worldwide, having prevailed against the early pulsatile tube compression pumps and ventricular pumps. In recent years, centrifugal pumps have increasingly competed with roller pumps as systemic blood pumps for cardiopulmonary bypass and have become the preferred arterial pump in a variety of centers. Application of mechanical cardiac assistance has evolved from nonpulsatile roller pump support, followed by an era of pulsatile ventricular pumps to the rediscovery of the nonpulsatile flow mode with modern axial flow pumps.

Prosthetic Valve for Transluminal Delivery

InactiveUS20100004740A1Preventing substantial migrationEliminate the problemBalloon catheterHeart valvesVenous accessImplantation Site
A prosthetic valve assembly for use in replacing a deficient native valve comprises a replacement valve supported on an expandable valve support. If desired, one or more anchors may be used. The valve support, which entirely supports the valve annulus, valve leaflets, and valve commissure points, is configured to be collapsible for transluminal delivery and expandable to contact the anatomical annulus of the native valve when the assembly is properly positioned. Portions of the valve support may expand to a preset diameter to maintain coaptivity of the replacement valve and to prevent occlusion of the coronary ostia. A radial restraint, comprising a wire, thread or cuff, may be used to ensure expansion does not exceed the preset diameter. The valve support may optionally comprise a drug elution component. The anchor engages the lumen wall when expanded and prevents substantial migration of the valve assembly when positioned in place. The prosthetic valve assembly is compressible about a catheter, and restrained from expanding by an outer sheath. The catheter may be inserted inside a lumen within the body, such as the femoral artery, and delivered to a desired location, such as the heart. A blood pump may be inserted into the catheter to ensure continued blood flow across the implantation site during implantation procedure. When the outer sheath is retracted, the prosthetic valve assembly expands to an expanded position such that the valve and valve support expand at the implantation site and the anchor engages the lumen wall. Insertion of the catheter may optionally be performed over a transseptally delivered guidewire that has been externalized through the arterial vasculature. Such a guidewire provide dual venous and arterial access to the implantation site and allows additional manipulation of the implantation site after arterial implantation of the prosthetic valve. Additional expansion stents may be delivered by venous access to the valve.

Minimally invasive transvalvular ventricular assist device

A tiny electrically powered hydrodynamic blood pump is disclosed which occupies one third of the aortic or pulmonary valve position, and pumps directly from the left ventricle to the aorta or from the right ventricle to the pulmonary artery. The device is configured to exactly match or approximate the space of one leaflet and sinus of valsalva, with part of the device supported in the outflow tract of the ventricular cavity adjacent to the valve. In the configuration used, two leaflets of the natural tri-leaflet valve remain functional and the pump resides where the third leaflet had been. When implanted, the outer surface of the device includes two faces against which the two valve leaflets seal when closed. To obtain the best valve function, the shape of these faces may be custom fabricated to match the individual patient's valve geometry based on high resolution three dimensional CT or MRI images. Another embodiment of the invention discloses a combined two leaflet tissue valve with the miniature blood pump supported in the position usually occupied by the third leaflet. Either stented or un-stented tissue valves may be used. This structure preserves two thirds of the valve annulus area for ejection of blood by the natural ventricle, with excellent washing of the aortic root and interface of the blood pump to the heart. In the aortic position, the blood pump is positioned in the non-coronary cusp. A major advantage of the transvalvular VAD is the elimination of both the inflow and outflow cannulae usually required with heart assist devices.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products